8-K: Sonnet BioTherapeutics Reports Q1 2024 Results, Secures Funding Extension Through Asset Sales

Sonnet BioTherapeutics announced its first quarter fiscal year 2024 results, highlighting progress in clinical trials and securing additional funding through a public offering and the sale of net operating losses.

Summary

• Sonnet BioTherapeutics reported its financial results for the three months ended December 31, 2023, and provided a business update.
• The company successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering.
• They also received approval to sell New Jersey state net operating losses (NOLs) for expected net proceeds of $4.3 million.
• Enrollment for the Phase 1b portion of the SON-080 trial in chemotherapy-induced peripheral neuropathy (CIPN) has been completed.
• The company had $3.0 million in cash on hand and no debt as of December 31, 2023.
• Research and development expenses decreased to $0.6 million for the quarter, compared to $3.7 million in the same period of the previous year.
• General and administrative expenses also decreased to $0.7 million from $1.9 million year-over-year.
• The company expects the sale of NOLs to extend funding of projected operations into the third calendar quarter of 2024.
• A safety update from the SON-080 trial is expected during the first quarter of 2024, and safety data from the SON-1010 and atezolizumab combination study is expected in the first half of 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has made progress in its clinical programs and secured additional funding, the low cash balance and reliance on non-dilutive funding sources raise concerns. The significant reduction in expenses is a positive, but the overall financial situation is still precarious.

Positives

• The company successfully raised $4.55 million through a public offering, strengthening its financial position.
• The sale of New Jersey NOLs for $4.3 million will provide additional funding and extend the company's operational runway.
• The completion of enrollment in the Phase 1b portion of the SON-080 trial is a significant milestone.
• The publication of preclinical data on SON-1210 in a peer-reviewed journal enhances the credibility of the company's research.
• The company has significantly reduced both research and development and general and administrative expenses, demonstrating a focus on cost management.
• The company received a $0.8 million net cash refund from the research and development tax incentive program in Australia.

Negatives

• The company reported a net loss of $1.17 million for the quarter.
• The company's cash on hand was $3.0 million at the end of December 2023, which is relatively low for a clinical-stage biotech company.
• The company is relying on non-dilutive funding sources such as the sale of NOLs to extend its cash runway, which may not be sustainable long-term.
• The company has cancelled accrued but unpaid bonuses from previous years, which may impact employee morale.

Risks

• The company's ability to continue operations is dependent on securing additional funding.
• Clinical trial results may not be positive, which could impact the company's valuation and future prospects.
• The company faces competition from other biotechnology companies developing similar therapies.
• The company's reliance on tax credits and the sale of NOLs may not be a sustainable long-term funding strategy.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects the sale of NOLs to extend funding of its projected operations into the third calendar quarter of 2024 and anticipates safety data from ongoing clinical trials in the first half of 2024.

Management Comments

• This last quarter set the stage for an exciting year across Sonnets pipeline, highlighted by the progress of the combination study of SON-1010 and atezolizumab in platinum-resistant ovarian cancer (PROC), where we continue to expect safety data during the first half of 2024, commented Pankaj Mohan, Ph.D., Founder and CEO.
• We believe this trial will yield important safety data that could help position the asset for a potential partnering opportunity in this indication, as well as in diabetic peripheral neuropathy (DPN), both indications of high unmet medical need.
• On the operations side, we continue the work to optimize our cash usage and runway, including leveraging tax credits.
• As our pipeline continues to advance, we remain focused on areas for further operating expense reductions, said Jay Cross, CFO.
• Furthermore, we are diligently working to expand on our business development accomplishments, in an otherwise highly competitive environment.

Industry Context

This announcement reflects the challenges faced by many clinical-stage biotech companies in securing funding and advancing their pipelines. The focus on cost reduction and strategic partnerships is a common theme in the current biotech landscape. The company's focus on oncology and immunotherapies aligns with current trends in the pharmaceutical industry.

Comparison to Industry Standards

• The reduction in R&D expenses from $3.7 million to $0.6 million quarter-over-quarter is significant and suggests a major shift in spending strategy, which is not typical for companies at this stage of development.
• The reliance on non-dilutive funding sources like the sale of NOLs is a common strategy for smaller biotech companies to extend their cash runway, but it is not a long-term solution.
• The company's cash position of $3.0 million is relatively low compared to other clinical-stage biotech companies, which often have tens of millions of dollars in cash reserves.
• The company's focus on albumin-binding technology (FHAB) is a unique approach that differentiates it from competitors, such as companies developing traditional antibody-based therapies.
• The company's clinical programs are in early stages (Phase 1b), which is typical for companies of this size and age, but it also means that the company is still several years away from potential commercialization.

Stakeholder Impact

• Shareholders may be concerned about the company's low cash balance and reliance on non-dilutive funding.
• Employees may be affected by the cost-cutting measures and the cancellation of accrued bonuses.
• Customers and partners may be interested in the progress of the company's clinical trials and potential partnering opportunities.
• Creditors may be monitoring the company's financial situation and ability to meet its obligations.

Next Steps

• The company expects to receive net proceeds from the sale of New Jersey NOLs in February 2024.
• Safety updates from the SON-080 trial are expected during the first quarter of 2024.
• Safety data from the SON-1010 and atezolizumab combination study is expected in the first half of 2024.
• The company will continue to focus on cost reduction and business development.

Key Dates

Keywords

biopharmaceutical, immunotherapeutic, clinical trials, oncology, FHAB, SON-1010, SON-080, SON-1210, net operating losses, public offering